



FOR IMMEDIATE RELEASE

Contacts: Holly P. Glass
holly.glass@semprusbio.com
571.243.1952

Jan Saragoni
jan.saragoni@saragoniandco.com
617.592.2877

SEMPRUS BIOSCIENCES RAISES ADDITIONAL \$18 MILLION

Series B Financing to Support First Product Regulatory Clearance and Clinical Validation

CAMBRIDGE, MA – (December 13, 2010) Semprus BioSciences, a biomedical company developing products designed to address the 56,000 annual deaths and \$11.2 billion in infection and thrombus complication costs¹ from vascular access products, today announced the closing of an \$18 million Series B financing.

SR One, the corporate venture capital arm of GlaxoSmithKline (NYSE: GSK), and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm, co-led the financing. Previous Series A investors 5AM Ventures and Pangaea Ventures are also participating. Semprus has raised a total of \$28.5 million.

“Semprus has done an outstanding job since 5AM Ventures provided seed funding in 2007,” said Semprus BioSciences Chairman of the Board, Scott Rocklage, Ph.D. “Over the last three years, the team has pioneered the Semprus Platform and this capability will lead to a new standard of care by inhibiting microbial adhesion and thrombus accumulation on the surfaces of medical devices,” he said.

Semprus BioSciences spun out of the labs of biomedical researcher and Massachusetts Institute of Technology (MIT) Professor Robert Langer after winning the MIT \$100K Entrepreneurship Competition in 2007. Semprus’ proprietary platform also incorporates the research of Shaoyi Jiang, Ph.D., the Boeing-Roundhill Professor of Chemical Engineering at the University of Washington, who was also a visiting professor in Langer’s Lab.

The company’s first product line incorporating Semprus Sustain™ Technology signifies a breakthrough for the medical device industry. “The Semprus Sustain™ Technology is designed to extend the viability of long-term devices susceptible to complications due to microbial adhesion and thrombus formation,” said David L. Lucchino, the company’s Chief Executive Officer. “We expect our technology to facilitate overall improvements in medical device performance, medical procedures and patient outcomes.”

SR One Partner Simeon George, M.D. said, “Semprus’ technology elegantly reduces the attachment of bacteria and blood components on the surfaces of medical devices, which we believe can also lower healthcare costs. We see the platform expanding to next-generation products such as novel drug delivery surfaces, with the potential for improved clinical benefits across the medical device spectrum.”

As a result of this financing, Simeon George and John Sullivan, a Principal at Foundation Medical Partners, will join the Board of Directors, which is currently comprised of Scott Rocklage, Ph.D., Partner, 5AM Ventures and Semprus Chairman; Purnesh Seegopaul, Ph.D., Partner, Pangaea Ventures; Robert S. Langer,

¹ *Journal of Wound Care, February 2010 (Wilcott et al.), Chronic Wounds and the Medical Biofilm Paradigm.*

Sc.D., MIT Institute Professor; Mark Colella, Principal, 5AM Ventures (Board Observer) and David Lucchino, Chief Executive Officer, Semprus BioSciences.

In addition to its equity financing, Semprus BioSciences has secured \$2.5 million in funding to date from the U.S. Department of Defense, the U.S. Department of Energy, the National Institutes of Health and the National Science Foundation.

###

Visit www.semprusbio.com for additional information.

*Semprus Biosciences was selected as one of "50 Companies to Watch"
by Medical Devices & Diagnostics Industry magazine in June 2010.*